High-grade heart block associated with ibrutinib therapy

[1]  P. Ellinor,et al.  Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase , 2020 .

[2]  M. Ratain,et al.  Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. , 2020, JAMA oncology.

[3]  P. Ellinor,et al.  Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK. , 2020, Circulation.

[4]  Yanwei Xing,et al.  Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation , 2020, Redox biology.

[5]  A. Marra,et al.  Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia , 2019, Clinical Cancer Research.

[6]  D. Roden,et al.  Cardiovascular Toxicities Associated With Ibrutinib. , 2019, Journal of the American College of Cardiology.

[7]  Yanwei Xing,et al.  Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. , 2019, Heart rhythm.

[8]  A. Alencar,et al.  Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. , 2019, The Lancet. Haematology.

[9]  G. Keller,et al.  Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes , 2019, Stem cell reports.

[10]  J. Byrd,et al.  Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials , 2017, Haematologica.

[11]  Jeffrey A Jones,et al.  Ventricular arrhythmias and sudden death in patients taking ibrutinib. , 2017, Blood.

[12]  J. Healey,et al.  The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. , 2016, Blood.

[13]  D. Roden,et al.  Abstract 14587: Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton’S Tyrosine Kinase (BTK) Used in Cancer Therapy , 2015, Circulation.

[14]  M. Keating,et al.  Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. , 2014, Blood.

[15]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[16]  Y. Hiroi,et al.  Notch1 in Bone Marrow–Derived Cells Mediates Cardiac Repair After Myocardial Infarction , 2011, Circulation.